NECFA
SGTX

New England Capital Financial Advisors’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

New England Capital Financial Advisors’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3
Closed -$38 – 448
2023
Q1 		$38 Hold
3
– – ﹤0.01% 430
2022
Q4 		$30 Buy
+3
New +$17 ﹤0.01% 437

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

New England Capital Financial Advisors's SGTX Position: Q2 2023 in Review

New England Capital Financial Advisors sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 3 shares — an estimated $38 sold.

New England Capital Financial Advisors first reported a position in SGTX in Q4 2022 and held it in 2 quarters. The position peaked at $38 in Q1 2023. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

  • New England Capital Financial Advisors reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • New England Capital Financial Advisors sold 3 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $38.
  • New England Capital Financial Advisors first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • New England Capital Financial Advisors's Sigilon Therapeutics, Inc. Common Stock position peaked at $38 in Q1 2023.
  • 16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on New England Capital Financial Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.